OSE Immunotherapeutics Organizes Webcast on Phase 2 CoTiKis Study on September 2
The biotechnology company announced the holding of an online session bringing together international experts on chronic inflammatory bowel diseases (IBD) around its flagship program. The meeting will be held live in English, with optional French subtitles.
IL-7 Receptor and CoTiKis Study Results on the Agenda
OSE Immunotherapeutics indicated on August 28, 2026 that the webcast will focus on the biology of the IL-7 receptor and the results of the Phase 2 clinical study CoTiKis in ulcerative colitis.
The discussion will also address development plans in chronic pouchitis, followed by a question and answer session with the audience. The event will take place on September 2, 2026 at 18:00 CET (12:00 ET).
Key Opinion Leaders and OSE Executives United
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company specified that the invited key opinion leaders are Prof. Laurent Peyrin-Biroulet (CHRU Nancy, France) and Dr. Maia Kayal (Icahn School of Medicine at Mount Sinai, New York).
They will be joined by Marc Le Bozec, Chief Executive Officer, and Dr. Aurore Morello, Scientific Director. OSE Immunotherapeutics, based in Nantes and Paris, is listed on Euronext.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
